How should I manage a patient with a urine culture growing Streptococcus mitis/oralis group at 10,000–25,000 colony‑forming units per milliliter?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Do Not Treat This Culture Result

In a patient without urinary symptoms, this urine culture growing Streptococcus mitis/oralis group at 10,000–25,000 CFU/mL represents either contamination or asymptomatic bacteriuria and should not be treated. 1

Key Decision Points

1. Assess for Urinary Symptoms

The critical first step is determining whether the patient has any urinary symptoms:

  • Dysuria (painful urination)
  • Urgency (sudden compelling need to urinate)
  • Frequency (urinating more often than usual)
  • Suprapubic pain
  • Hematuria (blood in urine)
  • New or worsening incontinence

If the patient has NONE of these symptoms, this is asymptomatic bacteriuria (ABU) and should not be treated 1.

2. Understanding the Organism and Colony Count

Streptococcus mitis/oralis group is part of normal oral flora and is an uncommon urinary pathogen. Its presence in urine at this low colony count (10,000–25,000 CFU/mL) strongly suggests:

  • Contamination from periurethral/perineal flora during collection
  • Colonization without infection (asymptomatic bacteriuria)

The colony count is below the traditional 100,000 CFU/mL threshold for asymptomatic bacteriuria 1. While lower counts (≥10² CFU/mL) can indicate true infection in symptomatic patients 2, this organism at this count in an asymptomatic patient does not warrant treatment.

3. Strong Guideline Recommendations Against Treatment

The 2024 EAU guidelines provide strong recommendations to NOT screen or treat asymptomatic bacteriuria in 1:

  • Women without risk factors
  • Patients with well-regulated diabetes
  • Postmenopausal women
  • Elderly institutionalized patients
  • Patients with dysfunctional/reconstructed lower urinary tract
  • Renal transplant recipients
  • Patients before arthroplasty surgery
  • Patients with recurrent UTIs

4. Exceptions Requiring Treatment

Only treat asymptomatic bacteriuria in these specific situations 1:

  • Pregnant women (weak recommendation) - use standard short-course treatment or single-dose fosfomycin
  • Before urological procedures that breach the mucosa (strong recommendation) - such as transurethral resection, cystoscopy with biopsy, or stone manipulation

Clinical Reasoning

The 2024 guidelines emphasize that asymptomatic bacteriuria represents commensal colonization, not infection 1. Treating ABU:

  • Increases antimicrobial resistance without clinical benefit
  • May eliminate protective bacterial strains that prevent symptomatic UTI
  • Wastes healthcare resources and exposes patients to unnecessary antibiotic side effects

The 2024 JAMA Network Open consensus statement reinforces that avoiding overtesting and overtreatment of ABU is essential to preserving antimicrobial effectiveness 3. A 2017 systematic review showed 45% of patients inappropriately received antibiotics for ABU 3.

Common Pitfalls to Avoid

  1. Do not reflexively treat positive urine cultures - the culture result alone does not equal infection
  2. Do not confuse fever from other sources with UTI - especially in elderly patients, fever often has non-urinary causes 3
  3. Do not assume low colony counts are always insignificant - but this applies only to symptomatic patients with typical uropathogens (E. coli, Klebsiella, etc.), not oral flora like S. mitis/oralis
  4. Do not order urine cultures on asymptomatic patients - this creates unnecessary treatment dilemmas

If the Patient IS Symptomatic

If this patient actually has dysuria, urgency, frequency, or suprapubic pain, then:

  • The low colony count and unusual organism still suggest contamination rather than true infection
  • Repeat the culture with careful midstream clean-catch technique
  • Consider alternative diagnoses (vaginitis, sexually transmitted infection, urethritis)
  • True UTIs with S. mitis/oralis are exceedingly rare 4 and typically occur only in severely immunocompromised hosts or neonates

The laboratory note stating "susceptibility not normally performed on this organism" reinforces that this is not considered a typical urinary pathogen.

References

Related Questions

Should a urine culture with 15,000 CFU/mL (colony-forming units per milliliter) Nakaseomyces glabratus (formerly Candida glabrata) be treated?
In a male patient with a urine culture showing yeast greater than 100,000 colony‑forming units per milliliter, what is the clinical significance and recommended management?
Is a urine culture showing Lactobacillus species at 30,000 CFU/mL clinically significant, and should it be treated?
In a male patient with a urine culture revealing 30,000 CFU/mL Enterococcus, does this require antimicrobial therapy?
How should I interpret a PCR urine test that shows Enterococcus at 10^5‑10^6 copies per milliliter?
For a patient on clonidine three times daily for hypertension whose systolic blood pressure remains 140–150 mm Hg, what are the appropriate next management steps?
When should the peak anti‑Xa level be drawn for low‑molecular‑weight heparin in relation to the fourth dose?
Is the Vanderbilt parent questionnaire alone sufficient to diagnose ADHD?
What is the best prescription topical antibiotic cream for a possible secondary bacterial infection of bug bites?
What are the current recommended antibiotic regimens for common adult infections such as community‑acquired pneumonia, uncomplicated urinary‑tract infection, MRSA skin infections, and ESBL‑producing Enterobacterales, including new agents, treatment durations, and fluoroquinolone restriction?
What is the annual cost of PCSK9 inhibitors (evolocumab or alirocumab) compared with inclisiran for a patient on high‑intensity statin plus ezetimibe with LDL‑C approximately 50 mg/dL?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.